Natera Q2 Revenue Jumps 38% to $753M, Loss Narrows; Oncology Volumes Surge 57%
NTRA has more than doubled off its 52-week low of $135.75.
Summary
Natera's Q2 2026 revenue rose 38% to $752.8M, with oncology test volumes up 57%. Net loss narrowed to $67M, and gross margins improved. Cash position remains strong at $1.09B.
Key Events · Earnings and Guidance · NTRA
-
Revenue Surges 38% to $752.8M
Total revenue for Q2 2026 hit $752.8 million, up from $546.6 million in the prior-year period, as strong test volume growth and higher average selling prices drove the top line.
-
Oncology Volumes Jump 57%
Oncology test volumes processed soared 57% year-over-year to approximately 296,700 units, underscoring the continued commercial momentum for Signatera.
-
Net Loss Narrows to $67M
The net loss improved to $67.0 million from $100.9 million in the year-ago quarter, aided by revenue growth and operating leverage.
-
Gross Margin Expands to 64.5%
Gross margin widened to 64.5% from 63.4% a year ago, benefiting from a favorable product mix and higher reimbursement.
Analysis · NTRA · Industrial Applications And Services
A standout second quarter saw revenue climb 38% year-over-year to $752.8 million, fueled by a 57% surge in oncology test volumes. The net loss narrowed to $67 million from $101 million a year ago, while gross margins expanded to 64.5%. With $1.09 billion in cash at quarter-end, the company has ample runway. In a separate development, Executive Chairman Matthew Rabinowitz adopted a 10b5-1 trading plan for up to 200,000 shares—a pre-planned move that does not detract from the positive operational momentum.
At the time of this filing, NTRA was trading at $275.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $38B. The 52-week trading range was $135.75 to $288.04. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.